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The human cathelicidin antimicrobial protein-18 and its C
terminal peptide, LL-37, displays broad antimicrobial
activity that is mediated through direct contact with the
microbial cell membrane. In addition, recent studies reveal
that LL-37 is involved in diverse biological processes such
as immunomodulation, apoptosis, angiogenesis and wound
healing. An intriguing role for LL-37 in carcinogenesis is
also beginning to emerge and the aim of this paper was to
explore if and how LL-37 contributes to the signaling
involved in tumor development. To this end, we investi-
gated the putative interaction between LL-37 and growth
factor receptors known to be involved in tumor growth and
progression. Among several receptors tested, LL-37 bound
with the highest afﬁnity to insulin-like growth factor 1
receptor (IGF-1R), a receptor that is strongly linked to
malignant cellular transformation. Furthermore, this
interaction resulted in a dose-dependent phosphorylation
and ubiquitination of IGF-1R, with downstream signaling
conﬁned to the mitogen-activated protein kinase/extra-
cellular signal-regulated kinase (ERK)-pathway but not
affecting phosphatidylinositol 3 kinase/Akt signaling. We
found that signaling induced by LL-37 was dependent on
the recruitment of b-arrestin to the fully functional IGF-
1R and by using mutant receptors we demonstrated that
LL-37 signaling is dependent on b-arrestin-1 binding to
the C-terminus of IGF-1R. When analyzing the biological
consequences of increased ERK activation induced by LL-
37, we found that it resulted in enhanced migration and
invasion of malignant cells in an IGF-1R/b-arrestin
manner, but did not affect cell proliferation. These results
indicate that LL-37 may act as a partial agonist for IGF-
1R, with subsequent intra-cellular signaling activation
driven by the binding of b-arrestin-1 to the IGF-1R.
Functional experiments show that LL-37-dependent acti-
vation of the IGF-1R signaling resulted in increased
migratory and invasive potential of malignant cells.
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Introduction
Antimicrobial peptides, AMPs, are important compo-
nents of the innate immune system in most living
organisms because they exhibit broad antimicrobial
function against bacteria, fungi, yeast and viruses
(Radek and Gallo, 2007). A common feature of AMPs
is their cationic and amphiphatic structure, allowing
interaction with and disruption of microbial mem-
branes, which typically contain a high degree of negative
charge (Gennaro and Zanetti, 2000). In mammals, two
important subgroups of AMPs have been described:
defensins and cathelicidins. Cathelicidins are stored in
cells in an unprocessed form, each comprising a highly
conserved signal sequence, a sequence homologous to
the cathepsin L inhibitor cathelin and a more variable
bioactive C-terminus. In humans, only one cathelicidin
has been identiﬁed; the unprocessed form is termed
human cationic antimicrobial protein 18 (hCAP-18) and
the cleaved, mature C-terminal peptide consisting of 37
amino acids is accordingly named LL-37 (Zanetti, 2004).
hCAP-18 is expressed in leukocytes and epithelial cells
and LL-37 is cleaved and released from the precursor
through the action of serine proteinases. In physiologi-
cal conditions, LL-37 assumes an alpha helical structure
and displays broad antimicrobial activity, neutralizes
lipopolysaccharide bioactivity (Turner et al., 1998) and
acts as a chemoattractant for inﬂammatory and immune
cells (De et al., 2000).
The functional repertoire of LL-37 is rapidly expand-
ing and the peptide is currently implicated in multiple
processes such as angiogenesis, wound healing and
apoptosis (Heilborn et al., 2003; Barlow et al., 2006;
Shaykhiev et al., 2008; Chamorro et al., 2009). Given
their cytotoxic activity at high concentrations, LL-37
and other antimicrobial proteins have been proposed as
therapeutic agents for the treatment of cancer (Mader
and Hoskin, 2006). In contrast, several recent publica-
tions propose a role for LL-37 in tumor development
(Heilborn et al., 2005; Coffelt and Scandurro, 2008; von
Haussen et al., 2008). Cumulative data from these
reports show overexpression of hCAP-18/LL-37 in
breast, ovarian and lung cancer cells and that treatment
with LL-37 peptide stimulates the proliferation, migra-
tion and invasion of cancer cells as well as promoting
tumor growth and metastasis in animal models (Heil-
born et al., 2005; Coffelt et al., 2008; von Haussen et al.,
2008; Weber et al., 2009). Thus, LL-37 is suggested to
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from stromal cells surrounding cancer, although the
mechanisms responsible for these effects are unknown.
One hypothesis is that LL-37 exerts its oncogenic effects
through activation of speciﬁc signaling pathways. So
far, several receptor pathways have been implicated in
the non-antimicrobial effects induced by LL-37. The
G-protein coupled receptor, formyl peptide-receptor-
like-1, is involved in stimulation of chemotaxis and
angiogenesis (Koczulla et al., 2003) and the purinergic
P2X7 ion channel participates in apoptosis, neutrophil
recruitment and cytokine processing stimulated by
LL-37 (Elssner et al., 2004). Furthermore, LL-37 was
proposed to transactivate the epidermal growth factor
receptor, EGFR, inducing cytokine release and cell
migration (Tjabringa et al., 2003; Tokumaru et al.,
2005). However, the tumorigenic effects associated with
LL-37 could not be fully explained through the interac-
tion with any of these receptors (Weber et al., 2009).
Therefore, the main aim of this study was to explore
additional putative receptors and pathways for LL-37.
Receptor tyrosine kinases constitute an important
family of plasma membrane receptors, composed of 59
related members with similar structural and functional
characteristics (Hubbard and Miller, 2007). Among
them, insulin-like growth factor 1 receptor (IGF-1R) is
one of the crucial players in cancer development (Adams
et al., 2000; Baserga, 2000; Larsson et al., 2005). Most
tumor cell types including breast, prostate and lung
cancer express high amounts of IGF-1R and conditions
in the tumor microenvironment, such as hypoxia, can
lead to enhanced responsiveness to IGF-1 (All-Ericsson
et al., 2002; LeRoith and Roberts, 2003; Ulfarsson et al.,
2005; Pollak, 2008). In addition, IGF-1R confers
protection against apoptosis, maintains the malignant
phenotype and protects against antitumor therapy
(Girnita et al., 2000a; Baserga et al., 2003; Pollak,
2008). The multiple functions of IGF-1R in cancer
development coupled with its redundancy in physiolo-
gical cell growth make this receptor an attractive target
for cancer treatment (Girnita et al., 2000b, 2004;
Baserga, 2005; Menu et al., 2006; Clemmons, 2007;
Tornkvist et al., 2008; Yin et al., 2010). Owing to its
ubiquitous expression pattern and its role in promoting
cell growth, strategies to inhibit IGF-1R actions are
being pursued for treatment of diverse conditions such
as short stature, atherosclerosis and diabetes (LeRoith
and Roberts, 2003; Razuvaev et al., 2007; Pollak, 2008).
To date IGF-1R has only one known ligand, IGF-1 a
polypeptide hormone with a high degree of structural
similarity to human proinsulin.
Results
LL-37 associates with IGF-1R in vitro
First, we investigated the potential binding of LL-37 to
several growth factor receptors using a sandwich enzyme-
linked immunosorbent assay. Antibodies against IGF-1R,
insulin receptor (IR), ﬁbroblast growth factor receptor,
platelet-derived growth factor receptor (PDGFR), Her2-
neu, vascular endothelial growth factor receptor (VEGFR)
and epidermal growth factor receptor (EGFR) were
employed to capture the corresponding receptors. Anti-
bodies for LL-37 were used as positive and mouse and
rabbit isotype immunoglobulin G as negative controls.
Total protein lysate from MCF-7 cells, which are known to
express these receptors, was added to the capture antibody.
After the addition of LL-37, binding to respective receptors
was detected using antibody against LL-37. Intriguingly,
IGF-1R showed the highest afﬁnity for LL-37 (Figure 1)
and therefore we decided to investigate in detail the
putative functional implications of this interaction.
LL-37 associates with IGF-1R in a cell system
We next examined whether LL-37 binds IGF-1R in a
more physiological context, in living cells. In the ﬁrst set
of experiments, MCF-7 cells were cultured overnight in
the absence of serum and then treated for 10min with
9mg/ml of LL-37. The cells were harvested, IGF-1R was
immunoprecipitated from total protein lysates with an
anti-IGF-1R antibody and the immunoprecipitate ana-
lyzed by western blot with an anti-LL-37 antibody. As
shown in Figure 2a, LL-37 co-immunoprecipitated with
IGF-1R in MCF-7 cells both in the presence and
absence of IGF-1. To verify the speciﬁcity of the
association, we used small interfering RNA (siRNA)
to downregulate IGF-1R expression in MCF-7 cells. In
the absence of IGF-1R, following siRNA treatment, the
IGF-1R antibody failed to co-immunoprecipitate LL-
37, indicating a speciﬁc binding of LL-37 to IGF-1R
(Figure 2b). As an alternative experimental model, we
used mouse embryonic ﬁbroblasts with a targeted
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Figure 1 LL-37 associates with IGF-1R in vitro. A sandwich
enzyme-linked immunosorbent assay, demonstrating the binding of
LL-37 to different membrane receptors. Antibodies against IGF-1R,
insulin receptor (IR), Her2neu, ﬁbroblast growth factor receptor
(FGFR), epidermal growth factor receptor (EGFR), platelet-derived
growth factor receptor (PDGFR) and vascular endothelial growth
factor receptor (VEGFR) were employed to capture the correspond-
ing receptors. Antibodies for LL-37 were used as positive and mouse
and rabbit isotype immunoglobulin G as negative controls. Total
protein lysate from MCF-7 cells, known to express these receptors,
was added over the capture antibody. After the addition of LL-37,
binding to receptors was detected using an antibody against LL-37,
horseradish peroxidase conjugated. The reactions were quantiﬁed by
measuring the absorbance and the relative LL-37 binding as
percentage of LL-37 binding to the anti-LL-37 antibodies is shown.
Mean values of three experiments are shown; bars, ±s.e.
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Oncogenedisruption of the IGF-1R (R  cells) or overexpressing
IGF-1R (Rþ). Consistent with the above results, the
IGF-1R immunoprecipitation showed a preferential
binding of LL-37 to Rþ over R  cells (Figure 2c).
Finally, we investigated the speciﬁcity of the LL-37/
IGF-1R interaction by using a pull-down assay followed
by in vitro ligand-receptor interaction. IGF-1R was
isolated by immunoprecipitation from Rþ or MCF-7
cells and the beads were incubated for 10min with
9mg/ml LL-37 or with the same concentration of the
3L–7L scrambled peptide—a synthetic peptide with
identical amino-acids composition as LL-37 but with
a slightly different order (Figure 2c).
Taken together, these ﬁndings show that both
endogenous and overexpressed IGF-1R can interact
with LL-37 in living cells.
Effects of LL-37 on IGF-1R signaling
Although our data clearly demonstrates that IGF-1R
and LL-37 are detected together in protein complexes,
it does not address whether this interaction is func-
tional and affects intracellular signaling. The next set
of experiments was designed to test this hypothesis.
One consequence of ligand (IGF-1) binding to IGF-1R
is phosphorylation of a group of three tyrosine residues
(Y1135, Y1131 and Y1136) within the activation loop of
IGF-1R. Therefore, we used an antibody raised against
IGF-1R phosphorylated at tyrosine 1131 to investigate
potential activation of IGF-1R following stimulation
with LL-37. MCF-7 breast cancer cells and cells over-
expressing IGF-1R (Rþ) were incubated in the absence
of serum with and without LL-37. Treatment with
LL-37 showed a clear increase in IGF-1R phospho-
rylation in both MCF-7 and Rþ cells (Figure 3a).
In agreement with a functional role, LL-37-induced
IGF-1R phosphorylation in a dose-dependent manner
up to LL-37 concentrations of 20mg/ml in both of these
cell lines (Figure 3b). Furthermore, LL-37-dependent
activation of the IGF-1R generated intracellular signal-
ing, as demonstrated by detection of dose-dependent
phosphorylation of extracellular signal-regulated kinase
(ERK)1/2 in parallel to phosphorylation of IGF-1R
(Figure 3b). We next investigated the time-course of
ERK activation induced by LL-37 in both MCF-7 and
Rþ cells and compared it with ERK activation by
IGF-1. Maximum activation of ERK signaling was
achieved after 10-min stimulation with LL-37, as with
IGF-1, with the latter being more potent in MCF-7
cells (Figure 3c). To better understand the role of
LL-37 in IGF-1R signaling, we also explored the
second major pathway known to be activated by
IGF-1R: the phosphatidylinositol 3 kinase (PI3K)/Akt
pathway. As expected, IGF-1 stimulation resulted in a
time-dependent phosphorylation of Akt in MCF-7 cells
whereas in contrast, LL-37 was ineffective at inducing
Akt phosphorylation (Figure 3c). Finally, we investi-
gated the speciﬁcity of the LL-37-induced ERK activa-
tion in MCF-7 cells, by using the 3L–7L scrambled
peptide. As shown in Figure 3d, 10-min stimulation with
IGF-1, LL-37 or serum similarly increases ERK
phosphorylation whereas a slight modiﬁcation of the
AA sequence of the LL-37 fully abolished its ERK
activation potential. Consistently, in a time-response
experiment, 3L–7L could not activate ERK signaling
although the cells were treated with the scrambled
peptides up to 60min (Figure 3d).
Taken together, these ﬁndings demonstrate that
LL-37 activates mitogen-activated protein kinase
(MAPK)/ERK signaling pathway through IGF-1R
without affecting the PI3K/Akt pathway. This is in
contrast to classical IGF-1 stimulation of the IGF-1R,
which activates both pathways.
Mechanism of LL-37-induced ERK activation
So far, our data indicate that LL-37 is a partial agonist
for IGF-1R as it binds and causes phosphorylation of
the receptor, induces MAPK/ERK activation but does
not affect the PI3K/Akt pathway. Recently, we showed
that ubiquitination of the IGF-1R represents an
important posttranslational modiﬁcation of the IGF-
1R, which together with receptor phosphorylation
modulates the IGF-1R-dependent activation of intra-
cellular signaling (Girnita et al., 2003; Sehat et al., 2008).
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Figure 2 LL-37 associates with IGF-1R in a cell system. MCF-7
cells were cultured overnight in the absence of serum and then
treated or not for 10min with 9mg/ml LL-37 in the presence or
absence of the IGF-1. The cells were harvested, IGF-1R was
immunoprecipitated from total protein lysates with an anti-IGF-
1R antibody and the levels of LL-37 binding were assayed by
western blot with an anti-LL-37 antibody. As loading control, the
total levels of IGF-1R were determined using an antibody against
IGF-1R (a). The IGF-1R/LL-37 association is speciﬁc: siRNA to
IGF-1R impaired IGF-1R/LL-37 association. MCF-7 cells were
treated with siRNA to downregulate IGF-1R expression or with
non-silencing siRNA (M) for 48h then treated or not for 10min
with 9mg/ml LL-37. The cells were harvested, IGF-1R was
immunoprecipitated from total protein lysates with an anti-IGF-
1R antibody and the levels of LL-37 binding were assayed by
western blot (b). The effect of IGF-1R silencing by siRNA was
assayed by measuring the total IGF-1R expression in the total cell
lysate; GAPDH was used as loading control (b). LL-37 binding to
the IGF-1R was measured by western blot as described above in
mouse embryonic ﬁbroblast with a targeted disruption of the IGF-
1R (R  cells) or overexpressing IGF-1R (Rþ)( c, left panel). The
speciﬁcity of the LL-37/IGF-1R interaction was investigated after
immunoprecipitation of the IGF-1R in MCF-7 or Rþ cells
followed by beads incubation for 10min with 9mg/ml LL-37 or
with the same concentration of 3L–7L scrambled peptide. The
binding of LL-37 or 3L–7L was measured by western blot as
described above (c, right panel).
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OncogeneIn addition, we showed that b-arrestin-1 is a key protein
involved in IGF-1R ubiquitination and MAPK/ERK
activation and that b-arrestin-1 is able to preferentially
direct IGF-1R signaling toward the MAPK/ERK path-
way versus the PI3K/Akt pathway (Girnita et al., 2005,
2007). We also demonstrated that the C-terminal part of
the IGF-1R is required for the preferential b-arrestin-1-
dependent ERK signaling (Girnita et al., 2007; Vasilca-
nu et al., 2008). Therefore, as a next step we explored the
mechanisms underlying LL-37-induced activation of
ERK. Expression of IGF-1R is required for the
activation of the MAPK/ERK pathway induced by
LL-37 and IGF-1 since phosphorylated ERK was not
detectable after 10-min stimulation with either agonist in
cells lacking IGF-1R (R ) (Figure 4a). Treatment with
serum served as a positive control demonstrating
functional MAPK/ERK signaling in these cells. Nota-
bly, stable re-expression of increasing number of IGF-
1R in R  cells (R12, 508 and Rþ cells) restored ERK
phosphorylation induced by LL-37 as well as IGF-1
(Figure 4a). In the next set of experiments, we used a
range of IGF-1R mutants, with inactive functional key
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Figure 3 Effects of LL-37 on IGF-1R signaling. LL-37 induces IGF-1R phosphorylation. MCF-7 and Rþ cells were serum-starved
for 24h and then stimulated with LL-37 or serum for 10min. Total protein lysates were analyzed by western blot for phosphorylated
IGF-1R using phospho-speciﬁc antibodies; expression of the total IGF-1R was used as loading controls (a). LL-37-induced IGF-1R
phosphorylation in a dose-dependent manner. Cell lysates from MCF-7 and Rþ cells stimulated with increased LL-37 concentrations
were prepared as described in (a). Protein lysates were analyzed by western blot for IGF-1R phosphorylation, IGF-1R expression,
ERK phosphorylation and ERK expression (b). Kinetics of LL-37-induced ERK activation. The cells were serum-depleted for 24h and
then stimulated with IGF-1 or LL-37 for 0, 2, 5, 10, 30 or 60min. The lysates were analyzed for pERK1/2 versus ERK1/2 and pAkt
versus Akt by western blotting (c). Speciﬁcity of the LL-37-induced ERK activation in MCF-7 cells. MCF-7 cells were stimulated for
10min with IGF-1, LL-37, serum or 3l–7l or were stimulated for different times with the 3L–7L scrambled peptide whereupon the cell
lysates were prepared as described in (a) and analyzed by western blot for ERK phosphorylation and ERK expression (d).
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Figure 4 Mechanism of LL-37-induced ERK activation. Expression of IGF-1R is required for the activation of the MAPK/ERK
pathway by LL-37. mouse embryonic ﬁbroblast cells lacking IGF-1R (R ) or expressing increased numbers of human IGF-1R (R12,
508 and Rþ cells) were serum-starved for 24h and treated with serum, LL-37 or IGF-1 for 10min and then assayed for ERK1/2
phosphorylation (a). LL-37-induced activation of ERK can occur independently of the tyrosine kinase signaling pathways TM (R 
cells stably transfected with IGF-1R kinase defective triple mutant, where the activation domain tyrosine residues 1131, 1135 and 1136
are mutated to alanine), SM (R  stably transfected with IGF-1R with a substrate binding Y950 mutation to alanine), CT (R  stably
transfected with IGF-1R and lacking the C-terminal), and SM-CT (R  stably transfected with IGF-1R with a Y950A mutation and
lacking the C-terminal), cells were serum-depleted for 24h and then stimulated as described in panel a (b). The LL-37 binding to the
D1245 IGF-1R was veriﬁed by using the CT cells. Wild-type or CT cells were cultured overnight in the absence of serum and then
treated or not for 10min with 9mg/ml LL-37. IGF-1R was immunoprecipitated from total protein lysates with an anti-IGF-1R
antibody and the levels of LL-37 binding were assayed by western blot with an anti-LL-37 antibody. As a loading control, the total
levels of IGF-1R were determined using an antibody against IGF-1R (b, lower panel). Effects of LL-37 stimulation on IGF-1R
ubiquitination. MCF-7 and Rþ cells were serum depleted for 24h and then either untreated or treated with the proteasome inhibitor
MG132 (PI) for 1h before 10-min stimulation with IGF-1 or LL-37. IGF-1R was immunoprecipitated from the cell lysates and equal
amounts of immunoprecipitates were fractionated and probed with an anti-ubiquitin antibody. Detection of the IGF-1R was used as a
loading control (upper panel). IGF-1R ubiquitination in both MCF-7 and Rþ cell lines was also veriﬁed by immunoprecipitating the
cell lysates with an antibody to ubiquitin (P4D1) and immunoblotting with an antibody recognizing IGF-1R (lower panel) (c).
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Oncogeneresidues, to identify the IGF-1R domains involved in
LL-37-induced MAPK/ERK activation. The following
cells and conditions were used: R  cells stably
transfected with mutant IGF-1Rs, (i) IGF-1R kinase
defective cells (TM) where the activation domain
tyrosine residues 1131, 1135 and 1136 are mutated to
alanine to prevent phosphorylation of the activation
loop; (ii) substrate binding defective mutants (SM)
where tyrosine 950, the binding site for the two major
IGF-1R substrates insulin receptor substrate (IRS) and
Shc, is mutated to alanine; (iii) C-truncated mutants
(CT) where the entire C-terminus of the IGF-1R is
truncated after the 1245 residue and (iv) SM-CT cells
that express IGF-1R with both truncated C-terminus
and the Y950A substitution. In all of the tested cell lines,
serum stimulation demonstrated functional MAPK/
ERK signaling (Figure 4b). Interestingly, LL-37-depen-
dent ERK activation required the presence of the IGF-
1R C-terminal part of IGF-1R because D1245 truncated
receptors failed to phosphorylate ERK in the presence
of LL-37 (Figure 4b). However, the binding of LL-37 to
IGF-1R was not affected by deletion of the C-terminus,
as demonstrated by co-immunoprecipitation (Figure 4b,
lower panel) indicating that the IGF-1R C-terminus is
essential for the transmission of the LL-37 signals but
not for its binding.
As we previously demonstrated that the C-terminus is
important for b-arrestin recruitment to the IGF-1R and
for IGF-1R ubiquitination (Girnita et al., 2005), we next
investigated the effects of LL-37 stimulation on IGF-1R
ubiquitination. MCF-7 and Rþ cells were incubated in
the absence of serum with the proteasome inhibitor
MG132, 1h before stimulation and harvesting. IGF-1R
was immunoprecipitated from the cell lysates and equal
amounts of the immunoprecipitates (Figure 4c) were
fractionated and probed with an anti-ubiquitin anti-
body. Control cells exhibited a low level of IGF-1R
ubiquitination whereas stimulation with IGF-1 or LL-
37 clearly increased IGF-1R ubiquitiation (Figure 4c).
In the presence of the proteasome inhibitor MG132, the
level of IGF-1R ubiquitination further increased sug-
gesting that ubiquitinated IGF-1R is targeted for
degradation. The high molecular weight (90–190kDa)
ubiquitin smear is typical for the multiple forms of
mono or polyubiquitinated IGF-1R (Girnita et al.,
2003). We veriﬁed the LL-37-induced IGF-1R ubiqui-
tination in both MCF-7 and Rþ cell lines by using a
complementary approach: immunoprecipitation with an
anti-ubiquitin antibody followed by detection with anti-
IGF-1R antibody (Figure 4c, lower panel).
Involvement of b-arrestin-1 in LL-37-induced IGF-1R
signaling
The above set of experiments were designed to test the
hypothesis that preferential routing of the LL-37
signaling through ERK pathway is dependent on the
C terminus of IGF-1R and is mediated by ubiquitina-
tion of IGF-1R. On the basis of our previous ﬁndings
that IGF-1R stimulation by its cognate ligand (IGF-1)
recruits b-arrestin-1 to the IGF-1R to activate ERK
signaling, we wanted to test whether LL-37 also uses a
b-arrestin-1-dependent mechanism. MCF-7 and Rþ
cells were cultured overnight in the absence of serum
and stimulated with IGF-1 or LL-37. Confocal micro-
scopy was used to explore whether LL-37 mediates
recruitment of b-arrestin-1 to the plasma membrane. As
shown in Figure 5a, under unstimulated conditions, in
both MCF-7 and Rþ cell lines, endogenous b-arrestins
are diffusely scattered in the cytoplasm as determined
by immunostaining with an antibody that detects both
b-arrestin isoforms. LL-37 stimulation clearly induced
formation of b-arrestin-1 signaling complexes similar
to IGF-1 (Figure 5a). The presence of IGF-1R and
b-arrestin-1 in these signaling complexes was demon-
strated by co-immunoprecipitation followed by western
blot (Figure 5b). Intriguingly, in MCF-7 cells, the IGF-
1R that co-immunoprecipitate with b-arrestin-1 after
LL-37 treatment migrate slightly slower than the one
that recruits b-arrestin-1 after IGF-1 stimulation,
perhaps because of different ubiquitination type induced
by different ligands. To test the dependency of MAPK/
ERK signaling on this association, we downregulated
b-arrestin-1 expression by siRNA in MCF-7 cells
(Figure 5c, upper panel). In agreement with our
hypothesis, ERK phosphorylation induced by LL-37
was severely impaired by downregulation of b-arrestin-1
(Figure 5c, lower panel). Taken together, these experi-
ments demonstrate that LL-37 binding to IGF-1R
activates MAPK/ERK signaling and that this process
is dependent on b-arrestin-1 recruitment and IGF-1R
ubiquitination.
Biological effects of LL-37 activation of ERK signaling
So far we have demonstrated that LL-37-mediated
activation of the IGF-1R results in receptor phosphor-
ylation, b-arrestin-1 recruitment and subsequent activa-
tion of the ERK signaling pathway. In the next set of
experiments, we investigated the biological effects of this
activation. First, we evaluated the effects of LL-37 on
cell proliferation. MCF-7 cells were serum-starved
overnight and then stimulated with LL-37, IGF-1 or
10% serum for 48h. Compared with serum-free
controls, IGF-1 and serum clearly stimulated a 1.8 and
2.4-fold increase in cell number, respectively. LL-37 had
a minor effect on cell proliferation (Supplementary
Figure 1), suggesting that in the absence of an activated
PI3K pathway, ERK activation is not sufﬁcient to
sustain cell proliferation. We next investigated the
effects of LL-37 signaling activation on other cellular
processes relevant to the cancer phenotype: cell migra-
tion and invasion. As a starting point, we used a
classical in vitro wound-healing assay to evaluate the
effects of LL-37 stimulation on cell migration. As shown
in Figure 6a, in the absence of serum, the wound failed
to close while serum stimulation-induced cell migration
with almost complete healing of the wound after 24h.
IGF-1 and LL-37 were equipotent in inducing cell
migration and gap closure of approximately 50% was
observed (Figure 6a). We used the same experimental
model to test whether the observed biological effect is
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As described above, we used siRNA targeting IGF-1R
or b-arrestin-1 to deplete the corresponding protein and
U0126, a highly selective inhibitor of MEK 1 and MEK
2 to chemically inhibit the ERK pathway. The effects of
siRNA targeting and ERK inhibition were veriﬁed by
WB (Figure 6b). IGF-1R or b-arrestin-1 downregula-
tion completely abrogated both IGF-1 and LL-37-
induced migration, consistent with the observation that
LL-37-activated ERK signaling is dependent on IGF-
1R and b-arrestin-1 (Figure 6c and Supplementary
Figure 2). Moreover, chemical inhibition of the ERK
pathway had similar effects, indicating a major role of
ERK signaling in cell migration (Supplementary Figure
2). In all of the above described experiments, we used
serum stimulation as positive control, to verify the
migratory capabilities of MCF-7 cells after various
treatments. In the absence of IGF-1R, b-arrestin-1 or
βarr1
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Figure 5 Involvement of b-arrestin-1 in LL-37-induced IGF-1R signaling. Subcellular distribution of b-arrestin-1 after LL-37 or IGF-
1 stimulation. MCF-7 and Rþ cells were cultured overnight in the absence of serum and then either remained unstimulated (left
panels) or were stimulated with IGF-1 (50ng/ml) for 30min (middle panels) or LL-37 (right panels). The cells were subsequently ﬁxed
and permeabilized. Cellular distribution of b-arrestin was visualized by immunolabeling with anti-b-arrestin antibody, then an
Alexa594 secondary antibody followed by confocal microscopy (a). The presence of IGF-1R and b-arrestin-1 in these signaling
complexes was demonstrated by co-immunoprecipitation followed by western blot (b). Requirement of b-arrestin-1 for IGF-1-induced
activation of ERK. MCF-7 cells were transfected with siRNA control (Mock) or b-arrestin-1 siRNA for 48h. The expression of b-
arrestin-1 was veriﬁed in the transfected stocks using total protein lysate of mouse embryonic ﬁbroblast cells, negative for b-arrestin-1
or b-arrestin-2 as negative and positive controls, respectively. The cells were serum-depleted overnight and stimulated with 10% serum
for 0, 5, 10 or 30min (left panel), or IGF-1 (50ng/ml) or LL-37 for 0, 2, 5, 10, 30 or 60min (right panel). Cell lysates were analyzed for
pERK1/2 versus ERK1/2 (c).
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OncogeneERK activity, although it was impaired, MCF-7 cells
still retain some migratory capabilities.
To further evaluate the effects of LL-37 on migration
of MCF-7, we made use of a modiﬁed Boyden chamber
assay (BD FluoroBlok cell culture inserts; BD
Biosciences-Europe, Erembodegem, Belgium) in which
the top and bottom compartments are separated by a
light-tight polyethylene terephthalate (PET) membrane
that efﬁciently blocks the transmission of light within
the range of 490–700nm, allowing detection of cells by
ﬂuorescent stain in a simpliﬁed and non-destructive
manner. Once labeled, cells migrate through the
membrane; they are easily detected by a bottom-reading
ﬂuorescence plate reader thus supporting kinetic migra-
tion and invasion assays. The MCF-7 cells were
ﬂuorescently labeled with BD Dilc12, before placing
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Figure 6 Effects of LL-37 on cell migration/invasion. The MCF-7 cells were grown to conﬂuent monolayers and were serum-starved
overnight. An artiﬁcial wound was made in the cell monolayer with a micropipette tip. After wounding, the cells were grown with IGF-
1 (50ng/ml), LL-37 (9mg/ml) or 10% serum for 24h. Wound closure was photographed and quantiﬁed by image analysis software and
the efﬁciency of wound healing was calculated as percentage compared with starting point (a). MCF-7 cells were transfected with b-
arrestin-1 siRNA or IGF-1R siRNA for 48h. MEK inhibitor (U0126) was added to MCF-7 at a ﬁnal concentration of 10mM, 30min
before stimulation. The efﬁciency of siRNA targeting and MEK inhibitor was detected by WB (b) The effect of IGF-1R
downregulation on serum, IGF-1 or LL-37-induced wound healing was investigated as describe above (c). Effect of LL-37 on cell
migration and invasion. BD BioCoat Tumor Invasion System chambers were used to investigate MCF-7 cell migration (d, upper panel)
and Matrigel invasion (d, lower panel) using LL-37 (9mg/ml), IGF-1 (50ng/ml) or serum 15%) as a chemoattractant for indicated
times. MCF-7 cells were transfected or not with b-arrestin-1 siRNA or IGF-1R siRNA or treated with MEK inhibitor (U0126) as
described in (b). The migration rate (d, upper panel) was calculated as the percentage of the migrating cells from the total cells added at
the start of the experiment on the upper chamber. The invasion rate (d, lower panel) was calculated as % of cells that invaded through
the Matrigel membrane divided by the migration rate. Each measurement was performed in triplicate. Columns, mean of three
experiments; bars, s.d.
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Oncogenethem on the top chamber, using either serum, LL-37 or
IGF-1 as a chemoattractant in the lower chamber.
Figure 6d upper panel, shows that after 24h, almost
80% of serum-stimulated cells had migrated through the
membrane, while in the negative control (serum free) no
cells migrated. In the presence of IGF-1 or LL-37 about
40% of the cells migrated. These results imply that LL-
37 efﬁciently stimulates cell migration along an LL-37
gradient in a time-dependent manner. By adding a
reconstituted basement membrane (Matrigel) onto the
pored membrane, we repeated the experiment to study
the effect of LL-37 on basement membrane invasion. Of
the serum-stimulated control cells that migrate, 55–60%
passed through the basement membrane after 24-h
incubation, while 30% of the LL-37 or 40% of IGF-1
stimulated, migrating cells, invaded through the Ma-
trigel (Figure 6d, lower panel). Once more we tested the
dependency of the observed migratory and invasive
phenotype on IGF-1R, b-arrestin-1 and ERK activity as
described above. As shown in Figure 6d, inhibition of
IGF-1R, b-arrestin-1 or ERK completely abrogated the
LL-37 and IGF-1-induced migration/invasion of MCF-
7 cells.
Effects of LL-37 on various cell lines
To investigate if IGF-1R-mediated LL-37 signaling is
cell-type dependent, we made use of a panel of
malignant cell lines expressing IGF-1R including lung
carcinoma (H1299), colon carcinoma (HCT116) and
breast cancer (MCF-7 and ZR75-1). As shown in
Figure 7, LL-37-induced ERK phosphorylation in all
cell lines tested, regardless of their origin.
Discussion
The purpose of this study was to investigate the
potential binding and agonistic activity of the pro-
inﬂammatory peptide LL-37 on different growth factors
receptors. We found that LL-37 binds IGF-1R and
behaves as a partial agonist, leading to receptor phospho-
rylation and ubiquitination and robust b-arrestin-1-
dependent activation of the MAPK/ERK pathway.
In contrast, stimulation of IGF-1R by LL-37 did not
affect PI3K activity suggesting that LL-37 is a natural
partial agonist for IGF-1R.
Epidemiological, clinical and experimental research
indicates that the IGF-1R signaling pathway has a
signiﬁcant impact on the development and progression of
cancer. Aberrant activation and/or overexpression of
I G F - 1 Ra r ea s s o c i a t e dw i t ha na g g r e s s i v ep h e n o t y p e ,
drug resistance and poor outcome in several tumors types
including melanoma, breast, lung and prostate cancer
(All-Ericsson et al., 2002; LeRoith and Roberts, 2003;
Larsson et al., 2005). Multiple reports show a clear
relationship between IGF-1 or IGF-binding proteins
levels and cancer risk, tumor promotion, progression
and outcome (LeRoith and Roberts, 2003; Baserga, 2005).
IGF-1R has also been implicated in metastasis and was
shown to interfere with expression of integrins, binding of
extracellular matrix proteins and activity of matrix
metalloproteinase 2 (Girnita et al., 2006; Samani et al.,
2007), all of which are involved in invasion and metastasis.
Phosphorylation was previously thought to be the
central process governing IGF-1R signaling because the
activated IGF-1R tyrosine kinase in turn phosphory-
lates substrates including IRS-1/2 and Shc, leading to
tumor transformation, overgrowth and metastasis
(LeRoith and Roberts, 2003; Larsson et al., 2005).
However, during the past decade, along with others, we
have challenged this view by demonstrating that besides
phosphorylation, ubiquitination is of critical importance
for the downstream signaling of IGF-1R (Girnita et al.,
2000a, 2003). Recently, we provided evidence that b-
arrestins, otherwise known to be involved in the
regulation of G protein-coupled receptors, serve as
adaptors for the ubiquitination process, connecting the
oncoprotein MDM2 to the IGF-1R (Girnita et al., 2005,
2007). In the case of G protein-coupled receptors, b-
arrestins were initially discovered as negative regulators
of G protein-mediated signaling by seven trans-
membrane receptors (7TMRs) (DeWire et al., 2007;
Rajagopal et al., 2010), although they were later shown
to be activators of cell signaling in their own rights
(DeWire et al., 2007; Rajagopal et al., 2010). Similarly,
in the case of IGF-1R, b-arrestins were demonstrated to
have a similar dual role: receptor downregulation and
activation of signaling (Girnita et al., 2005, 2007).
On the basis of the evidence provided in the present
paper, we propose a novel concept of biased signaling of
the IGF-1R. This concept is equivalent to the accepted
model of b-arrestin biased signaling for G protein-
coupled receptors: ligand binding to a G protein-
coupled receptor activates in a balanced manner both
G protein and b-arrestin-mediated pathways. Yet there
are numerous reports on biased signaling, where
signaling is mediated selectively through only one of
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Figure 7 Effects of LL-37 on various cancer cell lines. A panel of malignant cell lines expressing IGF-1R including lung carcinoma
(H1299), colon carcinoma (HCT116) and breast cancer (MCF-7 and ZR75-1) were serum-depleted for 24h and then stimulated with
10% serum, IGF-1 (50ng/ml) or LL-37 for 10min. The lysates were analyzed for pERK1/2 versus ERK1/2 by western blotting.
LL-37 is an IGF-1R agonist
A Girnita et al
360
Oncogenethese two pathways either by a biased agonist or by a
biased receptor (Violin and Lefkowitz, 2007). Analo-
gous to this model, we can consider two alternative
signaling models for IGF-1R: (1) the classical pathway,
originating on the substrate-binding site of the receptor
(Y950), where IGF-I binding to IGF-1R results in
receptor phosphorylation, increased kinase activity of
the receptor and subsequent auto-phosphorylation of
the tyrosine residues within IGF-1R; this pathway
requires the substrate-binding site Y950. (2) The b-
arrestin-1-mediated pathway requiring the C-terminus
of IGF-1R being highly dependent on or resulting in
IGF-1R ubiquitination. The natural IGF-1R agonist,
IGF-1, is a balanced agonist, typically activating both
Y950 and C-terminus (b-arrestin-1) signaling. In this
study, by using biased receptors, in which the IRS/Shc
and b-arrestin signaling pathways are dissociated
by mutation of the Y950, involved in IRS and Shc
binding or truncation of the C-terminus (b-arrestin-
binding), we show that LL-37 activates MAPK/ERK
pathways predominantly through the C-terminus signal-
ing pathway.
Our current model, in which LL-37 is a biased agonist
for IGF-1R capable of signaling mainly through b-
arrestin, provides evidence for the concept of biased
IGF-1R signaling and highlights the existence of natural
biased agonists for tyrosine kinase receptors. To our
knowledge, this is the ﬁrst study reporting a natural
biased agonist for a receptor tyrosine kinase.
It is generally accepted that cancer cells make use of
physiologic signals for proliferation and/or antiapopto-
sis to gain a growth advantage over normal cells. Besides
growth factors, such selective signals are generated by
the interaction of the ‘initiated’ cells with the surround-
ing tissue, including the adjacent inﬂammatory process
and are transmitted by plasma membrane receptors. The
notion that inﬂammation is a critical component of
tumor development and progression has long-been
appreciated (Balkwill and Mantovani, 2001; Coussens
and Werb, 2002). Based primarily on epidemiological
evidence, the major role of inﬂammation in cancer
development is now fully recognized. Although the
underlying molecular mechanisms are not completely
understood the present study reveals a new and
unexpected putative mechanism: activation of the highly
cancer relevant IGF-1R, by the proinﬂammatory
mediator, LL-37. A potential role for LL-37, and its
pro-form, hCAP-18, in cancer development and pro-
gression is being debated. hCAP-18/LL-37 is strongly
expressed in several human malignancies including
breast (Heilborn et al., 2005), lung (von Haussen
et al., 2008) and ovarian cancer (Coffelt et al., 2008).
Overexpression of the peptide in experimental cancers
was associated with increased growth and metastasis
in animal models and treatment with neutralizing anti-
LL-37 antibodies suppressed the growth of tumors in
ovarian cancer, suggesting a tumor-promoting effect
from LL-37 (Coffelt et al., 2008). LL-37 displays several
biological activities that could explain these effects:
LL-37 is reported to stimulate angiogenesis (Koczulla
et al., 2003) suppress apoptosis (Chamorro et al., 2009),
upregulate matrix metalloproteinases (Coffelt et al.,
2008) and was recently shown to recruit multipotent
mesenchymal stromal cells to the tumor environment
(Coffelt et al., 2009).
It is generally accepted that IGF-1R is a critical
regulator of cancer cell migration and proliferation
(Baserga et al., 2003; Samani et al., 2007). Yet, these two
cellular responses are mutually exclusive so at a given
time a cell can either migrate or divide. This apparent
contradiction could be explained by the fact that
IGF-1R induces different and even opposite cellular
responses through differential activation of intracellular
signaling pathways (Baserga, 2000). In this study, we
found that LL-37 preferentially stimulates the MAPK/
ERK signaling with no detectable PI3K/Akt activation.
This restricted signaling could not sustain cell prolifera-
tion. This is not surprising because the essential role
of PI3K/Akt signaling for the IGF-1R mitogenic
activity has long been appreciated (Dufourny et al.,
1997; Adams et al., 2000; Baserga, 2009). Nevertheless,
our results strongly suggest that LL-37 is a potent
mediator of migration and invasion in an IGF-1R-
dependent manner, validating the role of IGF-1R
in altering integrin signaling as well as affecting the
activity of extracellular matrix proteases (Doerr and
Jones, 1996; Dunn et al., 1998, 2001; Girnita et al., 2006;
Samani et al., 2007).
In summary, we demonstrate that LL-37 (i) forms a
complex together with the IGF-1R as shown by direct
binding in vitro and co-immunoprecipitation experi-
ments in cell system (ii) this complex requires the
presence of both IGF-1R and LL-37 as shown by
siRNA and Rþ/R  experiments and (iii) this binding
results in IGF-1R activation as demonstrated by IGF-
1R phosphorylation and ubiquitination. Moreover, our
results strongly support the concept of b-arrestin-
dependent activation of MAPK/ERK signaling by LL-
37 through IGF-1R, as shown by b-arrestin recruitment
to the IGF-1R following LL-37 stimulation, absence of
signaling and biological effects in b-arrestin-deﬁcient
cells or in cells expressing mutant IGF-1R defective in
b-arrestin binding. In this study, demonstrating for the
ﬁrst time a direct interaction between LL-37 and the
IGF-1R pathway, we reveal a mechanism whereby LL-
37 may promote essential processes of cancer metastasis
like cell migration and invasion. Our present data add
substantial evidence to the novel hypothesis that LL-37,
in addition to its antimicrobial and immunological
functions may be an attractive target for cancer therapy.
Materials and methods
Reagents
LL-37 (purity of 98%) was obtained from Polypeptide
Laboratories, Hillero ¨ d, Denmark. Monoclonal antibodies to
phosphotyrosine (PY99), ubiquitin (P4D1) and polyclonal
antibodies against IGF-1R (H-60), GAPDH (FL-335), b-
arrestin-1 (K-16), PDGFR (C-20), VEGFR, mouse immuno-
globulin G, rabbit immunoglobulin G and IR-a were from
Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA).
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(serine 473) and AKT were purchased from Cell Signaling
Technology (Danvers, MA, USA), as well as IGF-1R and
pIGF-1R (Tyr1131). EGFR, HER2/ErbB2 and ﬁbroblast
growth factor receptor antibodies were from Cell Signaling
Technology. The protein G sepharose was purchased from GE
healthcare (Uppsala, Sweden). Dynabeads protein G was from
Invitrogen (Carlsbad, CA, USA). Rabbit polyclonal anti-b-
arrestin-1 antibody (A1CT) was a kind gift from Robert
Lefkowitz (Duke University, Durham, NC, USA) and
was previously described (Attramadal et al., 1992). U0126
(1,4-diamino-2,3-dicyano-1,4-bis (2-aminophe-nylthio butadiene))
(Calbiochem, Nottingham, UK) was dissolved in dimethyl-
sulphoxide and used at a ﬁnal concentration of 10mM. Other
reagents unless stated otherwise were from Sigma (St Louis,
MO, USA).
Cell cultures
MCF-7 and ZR75-1 human breast cancer cell lines, H1299
human lung adenocarcinoma and HCT116 human colon
carcinoma cell lines were obtained from ATCC (via LGC
Promochem, Boras, Sweden). The MCF-7 and ZR75-1 cells
were grown in Dulbecco’s modiﬁed Eagle’s medium supple-
mented with 10% fetal bovine serum and 1% penicillin–
streptomycin. H1299 and HCT116 were cultured in Iscove’s
modiﬁcation of Dulbecco’s medium supplemented 10% fetal
bovine serum and 1% penicillin–streptomycin.
The R ,Rþ, R12, R508, 46, 48, 56 and 96 mouse cell lines
were a generous gift from Dr Renato Baserga (Thomas
Jefferson University, Philadelphia, PA, USA). The R  cells
are mouse embryonic ﬁbroblast with targeted disruption of the
IGF-1R gene (Sell et al., 1994). All other cell lines were created
following stable transfection of the R  cells with wild-type
human IGF-IR (Rþ, R12 and R508) or various mutants of
the human IGF-1R as previously described (Dews et al., 2000).
The following mutants were used: IGF-1R kinase defective
cells 48 (TM) where the activation domain tyrosine residues
1131, 1135 and 1136 are mutated to alanine to prevent
phosphorylation of the activation loop; substrate-binding
defective mutants 46 (SM) where tyrosine 950, the binding
site for the two major IGF-1R substrates IRS and Shc, is
mutated to alanine; C-truncated mutants 56(D1245) where the
entire C-terminus of the IGF-1R is truncated after the 1245
residue; SM-D1245 96 cells, which express IGF-1R with both
truncated C-terminus and the Y950A substitution. R12 cells
express about 7000receptors per cell while R508 expresses
17000 molecules of IGF-IR per cell. The cells were cultured in
Dulbecco’s modiﬁed Eagle’s medium supplemented with 10%
fetal bovine serum.
All cells were maintained in a humidiﬁed 5% CO2 atmo-
sphere at 371C.
Small interfering RNAs
Chemically synthesized, double-strand siRNAs were pur-
chased from Dharmacon (Pierce, Rockford, IL, USA). The
siRNA sequence that was used to deplete endogenous b-
arrestin-1 levels in MCF-7 cells was 50-AAAGCCUUCU
GUGCUGAGAAC-30 (Ahn et al., 2003). A non-silencing
RNA duplex (50-AAUUCUCCGAACGUGUCACGU-30), as
the manufacturer indicated, was used as a control. The siRNA
targeting human IGF-1R sequence 50-GCAGACACCUA
CAACAUCAUU-30 (Natalishvili et al., 2009) was used to
deplete endogenous IGF-1R levels in MCF-7 cells. The cells
were transfected at 40–50% conﬂuency, in a 25-cm
2 ﬂask,
using the DharmaFECT transfection reagent (Pierce) accord-
ing to the manufacturer’s instructions. After transfection, the
cells were incubated for 24h at 371C and then the media was
replaced with serum containing growth media. After addi-
tional incubation for 24h, cells were trypsinized and used for
further experiments.
Immunoprecipitation
Cells were cultured to subconﬂuency in six-well plates. After
indicated treatments, cells were lysed in phosphate-buffered
saline (PBS) with 1% Triton X-100, 0.5% sodium deoxycho-
late, 0.1% sodium dodecyl sulfate (PBS-TDS) as described
previously (Girnita et al., 2003). The protein concentration was
determined by the bicinchoninic acid assay (BCA protein assay
kit, Pierce). Dynabeads protein G (15ml) (Invitrogen) or
protein A/G—sepharose (15ml) (GE) and 1mg of antibody was
added to 500mg protein material. After overnight incubation
at 41C on a rotator platform, the immunoprecipitate was
collected, the supernatant discarded, the pellet was washed and
then dissolved in a sample buffer for sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS–PAGE).
SDS–PAGE and western blotting
Protein samples were dissolved in lithium dodecyl sulfate
(LDS) sample buffer (Invitrogen). Samples corresponding to
5–50mg of cell protein were analyzed by SDS–PAGE with a
4–12% gradient separation gel. Molecular weight markers
were run simultaneously. Following SDS–PAGE, the proteins
were transferred for one hour to nitrocellulose membrane
(Amersham Biosciences, Uppsala, Sweden) and then incubated
for 1h at room temperature in 5% (w/v) skimmed milk powder
in 0.02% (w/v) Tween 20, PBS, pH 7.5. Incubation with
appropriate primary antibody was performed for 1h at room
temperature. This was followed by washes with PBS and
incubation with either a horseradish peroxidase-conjugated or
biotinylated secondary antibody (Amersham Biosciences) for
1h at room temperature. Following incubation with biotiny-
lated secondary antibody, incubation with streptavidin-con-
jugated horseradish peroxidase was performed. Detection was
made with ECL (Pierce). The ﬁlms were scanned and
quantiﬁed by Fluor-S imager (Bio-Rad, Hercules, CA, USA).
Receptor-binding assay
Binding of LL-37 to different membrane receptors was assayed
using a sandwich enzyme-linked immunosorbent assay method
as previously described (Girnita et al., 2004). Brieﬂy, the
capture antibody directed against growth factor receptor to be
investigated, was bound to a solid phase in a polyvinylchloride
microtiter plate. After washing and blocking unspeciﬁc
binding sites with 2% bovine serum albumin in PBS, the
antigen (total protein lysate of MCF-7 cells) was added and
allowed to complex with the bound antibody. Unbound
proteins were then removed by three washes, after which LL-
37 was added to the plate followed by additional washes. The
detection antibody, a peroxidase labeled antibody against LL-
37 was allowed to bind the antigen, thus completing the
sandwich. The assay was then quantiﬁed by assessing the
amount of labeled secondary antibody bound to the matrix,
through the use of a colorimetric substrate reaction and
spectrophotometry (enzyme-linked immunosorbent assay
reader). The results were calculated as percentage of positive
control (LL-37 bound to the anti-LL-37 capturing antibodies).
Pull down assay and in vitro binding
IGF-1R was extracted from P6 or MCF-7 cells by immuno-
precipitation using Dynabeads protein G. After washing with
PBS, the pellet was incubated with 9mg/ml LL-37 or the same
LL-37 is an IGF-1R agonist
A Girnita et al
362
Oncogeneamount of peptide containing the scrambled amino acids of
LL-37 (3L–7L) in protein-binding buffer, overnight at 41Co n
a rotator platform. The beads and attached proteins were
separated by magnetic ﬁeld and washed three times with 0.1%
Tween 20 in protein-binding buffer and the pellet was
dissolved in lithium dodecyl sulfate sample buffer for analysis
by SDS–PAGE.
Immunoﬂuorescence MCF-7 and P6 cells were plated on
collagen-coated 35-mm glass bottom dishes (Wilco Wells,
Amsterdam, The Netherland) and serum starved for 8h
before stimulating with IGF-1 (50ng/ml) or LL-37 (9mg/ml)
for 10min. After washing three times with PBS, the cells were
ﬁxed with 4% paraformaldehyde diluted in PBS containing
calcium and magnesium before confocal analysis. For
immunostaining endogenously expressed b-arrestins, polyclonal
b-arrestin-1/2 antibody (A1CT), and anti-rabbit ALEXA 594
(Invitrogen) were used as primary and secondary antibodies,
respectively.
Cell proliferation assay
Cell proliferation was assessed using the Cell Proliferation kit
II (XTT) (Roche, Mannheim, Germany) according to the
manufacturer’s instructions.
Wound-healing assay
The MCF-7 cells were grown in Dulbecco’s modiﬁed Eagle’s
medium containing 10% fetal bovine serum at 371C and 5%
CO2 to form conﬂuent monolayers in 24-well plates and were
serum-starved overnight. An artiﬁcial wound was made in the
cell monolayer with a sterile plastic 10ml micropipette tip.
After wounding, the culture medium was removed and the cells
washed twice with serum-free medium to remove detached
cells. The cells were grown with IGF-1 (50ng/ml), LL-37 (9mg/
ml) or 10% serum for 24h. Wound closure was photographed
at the same spot, using an inverted microscope equipped with a
digital camera. The quantiﬁcation of the wound closure was
made using VisiCam 5.0 image analysis software (VWR,
Stockholm, Sweden).
In vitro migration and invasion
The migratory/invasive potential of the cells was tested using
BD BioCoat Tumor Invasion System (BD Biosciences-
Europe). It consists of a BD Falcon FluoroBlok 24-Multiwell
Insert Plate with an 8-mm pore size PET membrane coated
with Matrigel—for invasion or uncoated—for migration. Cells
were stained with Dilc12 for 2h and seeded at 5 10
4 cells in
500ml of serum-free Dulbecco’s modiﬁed Eagle’s medium onto
the apical chamber. In all, 750ml medium with IGF-1 (50ng/
ml), LL37 (9mg/ml) or 15% serum was added to the bottom
chamber for migration or both top and bottom chambers for
invasion. Equal seeding was veriﬁed by measuring the
top-ﬂuorescence. The plates were incubated at 371Ci na
humidiﬁed 5% CO2 atmosphere for 24h. During incubation,
the ﬂuorescence of the invaded cells on the bottom side of the
membrane was measured using a Tecan Inﬁnite M1000 plate
reader (Tecan Group Ltd., Ma ¨ nnedorf, Switzerland) at different
time points. For migration, the data were calculated as the
percentage of the migrating (bottom) cells of the total cells
added at the start of the experiment. The invasion rate was
calculated as number of cells that invaded through the
Matrigel membrane divided by the number of cells that
migrated through an uncoated membrane. Each measurement
was performed in triplicate.
Experimental reproducibility
All experiments were repeated at least three times with
consistent results.
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